MedTrace Logo

β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS

NCT00528359 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2008-03-11

No results posted yet for this study

Summary

The purpose of this study is to determine whether atypical antipsychotic drugs (commonly prescribed for treating schizophrenia) induce changes in anthropometry and metabolism, including alteration in insulin sensitivity and/or insulin secretion by the pancreas, when given to lean, non-diabetic, individuals who are antipsychotic drug(s)-naïve, and free of metabolic syndrome at enrollment.

Conditions

Interventions

DRUG

quetiapine or olanzapine or risperidone or aripiprazole

Sponsors & Collaborators

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    lead OTHER

Principal Investigators

  • Philippe M ORIOT, MD · Université Catholique de Louvain

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Completion
2007-02-28

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00528359 on ClinicalTrials.gov